

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ARGENTUM PHARMACEUTICALS LLC

Petitioner,

v.

NOVARTIS A.G.,

Patent Owner.

---

U.S. Patent No. 9,187,405

Issue Date: November 17, 2015

Title: S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis

---

*Inter Partes Review No. IPR2017-01550*

---

**Petition For *Inter Partes* Review**  
***35 U.S.C. §§ 311-319 and 37 C.F.R. § 42.100 et seq.***

## Table of Contents

I.	INTRODUCTION.....	1
A.	Brief Overview of the '405 Patent .....	3
B.	Brief Overview of the Prosecution History.....	5
C.	Brief Overview of the Grounds.....	6
D.	Brief Overview of the Scope and Content of the Prior Art.....	9
i.	International Publication No. WO 2006/058316 (“Kovarik,” EX1004).....	10
ii.	Thomson, <i>FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value</i> , CORE EVIDENCE, 1(3): 157-167 (2006) (“Thomson,” EX1005).....	11
iii.	U.S. Patent No. 6,004,565 to Chiba (“Chiba,” EX1006).....	13
iv.	Kappos, et al., <i>FTY720 in relapsing MS: results of a double- blind placebo-controlled trial with a novel oral immunomodulator</i> , JOURNAL OF NEUROLOGY 252(Suppl 2): 11/41, Abstract O141(2005) (“Kappos 2005,” EX1007).....	15
v.	Budde, et al., <i>First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients</i> , JOURNAL OF THE AMERICAN SOCIETY FOR NEPHROLOGY, 13:1073-1083 (2002) (“Budde,” EX1008)...	16
vi.	Kappos, et al., <i>A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis</i> , NEW ENGLAND JOURNAL OF MEDICINE, 362(5):387-401 (2010) (“Kappos 2010,” EX1038).....	17
E.	Brief Overview of the Level of Skill in the Art .....	19
II.	GROUND FORS STANDING.....	20
III.	MANDATORY NOTICES UNDER 37 C.F.R. §42.8 .....	21

IV.	STATEMENT OF THE PRECISE RELIEF REQUESTED .....	23
V.	STATEMENT OF NON-REDUNDANCY .....	23
VI.	CLAIM CONSTRUCTION .....	24
A.	“a subject in need” .....	24
B.	“A method for...” .....	25
VII.	BACKGROUND KNOWLEDGE IN THE ART PRIOR TO JUNE 27, 2006 .....	27
A.	Multiple Sclerosis.....	27
B.	Disease Modifying Therapies .....	28
C.	Fingolimod .....	29
D.	Loading Dose Regimens .....	32
VIII.	DETAILED EXPLANATION OF GROUNDS FOR UNPATENTABILITY .....	34
A.	[Ground 1] Claims 1-6 are Obvious under 35 U.S.C. § 103 over Kovarik and Thomson.....	34
i.	Claims 1, 3, and 5 .....	34
ii.	Claims 2, 4, and 6 .....	49
B.	[Ground 2] Claims 1-6 are Obvious under 35 U.S.C. § 103 over Chiba, Kappos 2005, and Budde. ....	50
i.	Claims 2, 4, and 6 .....	59
C.	[Ground 3] Claims 1-6 are Anticipated under 35 U.S.C. § 102 by Kappos 2010 (EX1038).....	60
i.	Claims 2, 4, and 6 .....	63
IX.	NO EVIDENCE OF UNEXPECTED RESULTS OR SECONDARY CONSIDERATIONS ARE ATTRIBUTABLE TO NOVEL ASPECTS OF THE CLAIMS .....	64

Patent No. 9,187,405  
Petition For *Inter Partes* Review

X. PAYMENT OF FEES UNDER 37 C.F.R. §§ 42.15(A) AND 42.103 ..... 66

XI. CONCLUSION ..... 66

XII. CERTIFICATE OF COMPLIANCE ..... 67

XIII. APPENDIX – LIST OF EXHIBITS ..... 68

## I. INTRODUCTION

Pursuant to 35 U.S.C. § 311 and § 6 of the America Invents Act (“AIA”), and 37 C.F.R. Part 42, Argentum Pharmaceuticals LLC, (“Petitioner”) requests review of U.S. Patent No. 9,187,405 to Peter C. Hiestand *et al.* (“the ’405 patent,” EX1001), issued on November 17, 2015, and assigned to Novartis A.G. (“Patent Owner”). Petitioner is filing, concurrently herewith, a Motion to Join pursuant to 35 U.S.C. § 315(c) and 37 C.F.R. § 42.122(b) the pending *inter partes* review involving the same patent and the same grounds of invalidity in *Apotex, Inc. and Apotex Corp. v. Novartis AG*, IPR2017-00854 (“Apotex IPR”), which was filed on February 3, 2017. The instant Petition is substantially identical to the Petition filed in the Apotex IPR.

The ’405 patent claims a method of administering fingolimod hydrochloride (“FTY720”), a previously known immunosuppressant, for the treatment of a subject with Relapsing-Remitting Multiple Sclerosis (“RR-MS”). The claimed method recites “a daily dosage of 0.5 mg” that was known and reported to be safe and pharmacologically effective in humans more than one year before the earliest effective filing date of the ’405 patent. For example, International Publication No. WO 2006/058316 (“Kovarik,” EX1004), teaches treating multiple sclerosis by administering a 0.5 mg oral daily dose of fingolimod hydrochloride.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.